Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration
Conclusions
A TE regimen can improve and stabilise patient outcomes in nAMD compared with PRN, with the potential to reduce the healthcare resource burden incurred from fixed monitoring requirements.
Source: British Journal of Ophthalmology - Category: Opthalmology Authors: Hatz, K., Prünte, C. Tags: Retina Original articles - Clinical science Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Eyes | Lucentis | Opthalmology | Ranibizumab Injection | Science | Study